Fondren Management LP Invests $1.24 Million in Shire PLC (SHPG)

Fondren Management LP purchased a new stake in shares of Shire PLC (NASDAQ:SHPG) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,241,000. Shire accounts for approximately 0.9% of Fondren Management LP’s portfolio, making the stock its 22nd biggest holding.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SeaCrest Wealth Management LLC acquired a new position in shares of Shire during the fourth quarter valued at $107,000. Avestar Capital LLC acquired a new stake in Shire in the fourth quarter worth about $116,000. Amica Retiree Medical Trust acquired a new stake in Shire in the fourth quarter worth about $120,000. BB&T Investment Services Inc. lifted its holdings in Shire by 1,672.3% in the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 786 shares during the period. Finally, Steward Partners Investment Advisory LLC acquired a new stake in Shire in the third quarter worth about $159,000. 19.75% of the stock is owned by institutional investors.

Shares of Shire PLC (NASDAQ SHPG) opened at $133.54 on Wednesday. Shire PLC has a 1-year low of $123.73 and a 1-year high of $192.15. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.97 and a quick ratio of 0.55. The firm has a market cap of $39,730.00, a PE ratio of 21.62, a price-to-earnings-growth ratio of 0.77 and a beta of 1.43.

Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.86 by $0.12. Shire had a net margin of 28.17% and a return on equity of 14.19%. The company had revenue of $4.14 billion during the quarter. During the same period in the previous year, the company posted $3.37 earnings per share. Shire’s revenue was up 8.9% compared to the same quarter last year. equities research analysts anticipate that Shire PLC will post 15.23 earnings per share for the current fiscal year.

The firm also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be issued a $0.8937 dividend. This represents a yield of 1.33%. This is an increase from Shire’s previous semiannual dividend of $0.15. The ex-dividend date is Thursday, March 8th. Shire’s dividend payout ratio is presently 17.30%.

SHPG has been the subject of several research analyst reports. Liberum Capital raised shares of Shire from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a “buy” rating in a report on Thursday, November 16th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Shire in a report on Thursday, November 16th. ValuEngine downgraded shares of Shire from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Zacks Investment Research downgraded shares of Shire from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $204.00.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with's FREE daily email newsletter.

Leave a Reply